[go: up one dir, main page]

LT3180363T - Sirp-alfa imunoglobulino sulieti baltymai - Google Patents

Sirp-alfa imunoglobulino sulieti baltymai

Info

Publication number
LT3180363T
LT3180363T LT15750744T LT15750744T LT3180363T LT 3180363 T LT3180363 T LT 3180363T LT 15750744 T LT15750744 T LT 15750744T LT 15750744 T LT15750744 T LT 15750744T LT 3180363 T LT3180363 T LT 3180363T
Authority
LT
Lithuania
Prior art keywords
sirp
fusion proteins
immunoglobulin fusion
alpha immunoglobulin
alpha
Prior art date
Application number
LT15750744T
Other languages
English (en)
Inventor
Kin-Ming Lo
Nora Zizlsperger
Aroop Sircar
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53872055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3180363(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of LT3180363T publication Critical patent/LT3180363T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LT15750744T 2014-08-15 2015-08-14 Sirp-alfa imunoglobulino sulieti baltymai LT3180363T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462038196P 2014-08-15 2014-08-15
PCT/EP2015/068798 WO2016024021A1 (en) 2014-08-15 2015-08-14 Sirp-alpha immunoglobulin fusion proteins

Publications (1)

Publication Number Publication Date
LT3180363T true LT3180363T (lt) 2019-11-25

Family

ID=53872055

Family Applications (1)

Application Number Title Priority Date Filing Date
LT15750744T LT3180363T (lt) 2014-08-15 2015-08-14 Sirp-alfa imunoglobulino sulieti baltymai

Country Status (22)

Country Link
US (1) US11021694B2 (lt)
EP (2) EP3643727A1 (lt)
JP (1) JP6764858B2 (lt)
KR (1) KR20170036796A (lt)
CN (1) CN107108748A (lt)
AU (1) AU2015303135B2 (lt)
BR (1) BR112017002646A2 (lt)
CA (1) CA2956126A1 (lt)
DK (1) DK3180363T3 (lt)
ES (1) ES2751915T5 (lt)
HR (1) HRP20191872T1 (lt)
HU (1) HUE046661T2 (lt)
IL (1) IL250622B2 (lt)
LT (1) LT3180363T (lt)
MX (1) MX377196B (lt)
PL (1) PL3180363T3 (lt)
PT (1) PT3180363T (lt)
RU (1) RU2017108203A (lt)
SG (1) SG11201701189TA (lt)
SI (1) SI3180363T1 (lt)
WO (1) WO2016024021A1 (lt)
ZA (1) ZA201701810B (lt)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4116331A1 (en) 2012-12-17 2023-01-11 PF Argentum IP Holdings LLC Treatment of cd47+ disease cells with sirp alpha-fc fusions
BR112015021921A2 (pt) * 2013-03-15 2017-08-29 Merck Patent Gmbh Anticorpos biespecíficos tetravalente
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
HUE054873T2 (hu) 2014-02-10 2021-10-28 Merck Patent Gmbh Célzott TGF-béta-gátlás
LT3180363T (lt) 2014-08-15 2019-11-25 Merck Patent Gmbh Sirp-alfa imunoglobulino sulieti baltymai
WO2016141357A1 (en) * 2015-03-05 2016-09-09 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
GEP20217326B (en) 2015-08-07 2021-11-25 Alx Oncology Inc Constructs having a sirp-alpha domain or variant thereof
SG10201913573UA (en) 2015-10-01 2020-03-30 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
CN107149682B (zh) * 2016-03-04 2022-01-04 复旦大学 一种靶向cd47的免疫检查点抑制剂药物组合物及其制备方法
WO2017184553A1 (en) * 2016-04-18 2017-10-26 Baylor College Of Medicine Cancer gene therapy targeting cd47
US11560433B2 (en) 2016-05-27 2023-01-24 Albert Einstein College Of Medicine Methods of treatment by targeting VCAM1 and MAEA
CN107459578B (zh) * 2016-05-31 2021-11-26 泰州迈博太科药业有限公司 一种靶向cd47与pd-l1的双功能融合蛋白
WO2018008470A1 (ja) * 2016-07-05 2018-01-11 国立大学法人神戸大学 抗腫瘍剤
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CN109790215B (zh) 2016-09-29 2023-06-30 北京韩美药品有限公司 异源二聚体免疫球蛋白构建体和其制备方法
CN114773471A (zh) 2016-10-20 2022-07-22 天境生物科技(上海)有限公司 新的cd47单克隆抗体及其应用
EP3534965A4 (en) 2016-11-03 2020-06-24 Trillium Therapeutics Inc. IMPROVEMENTS TO CD47 BLOCKING THERAPY BY HDAC INHIBITORS
CA3042581A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Enhancement of cd47 blockade therapy by proteasome inhibitors
CN106519036B (zh) * 2016-11-04 2019-06-11 新乡医学院 抗cd47和egfr的双功能蛋白及其制备方法与应用
PE20191080A1 (es) 2016-11-18 2019-08-20 Beijing Hanmi Pharmaceutical Co Ltd Anticuerpo biespecifico heterodimerico estructural de anticuerpo natural anti-pd-1/anti-her2 y metodo para preparar el mismo
CN108220228A (zh) * 2016-12-09 2018-06-29 上海迈泰君奥生物技术有限公司 无血清细胞培养基及高效表达重组蛋白质的方法
CA3047708A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A sirpalpha-41bbl fusion protein and methods of use thereof
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
CN110536693B (zh) 2017-01-05 2023-12-22 卡尔医学有限公司 Pd1-41bbl融合蛋白及使用其的方法
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
CN118184797A (zh) 2017-02-27 2024-06-14 沙塔克实验室有限公司 基于vsig8的嵌合蛋白
KR20190124247A (ko) 2017-02-27 2019-11-04 샤턱 랩스 인코포레이티드 Csf1r-기반 키메라 단백질
MY207687A (en) 2017-02-27 2025-03-12 Shattuck Labs Inc Tigit- and light-based chimeric proteins
CN108623689B (zh) * 2017-03-15 2020-10-16 宜明昂科生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制备方法和用途
JP2020511136A (ja) 2017-03-17 2020-04-16 フレッド ハッチンソン キャンサー リサーチ センター 免疫調節性融合タンパク質およびその使用
CN108864290B (zh) * 2017-05-08 2021-12-07 上海津曼特生物科技有限公司 双特异性重组蛋白及其应用
CA3066074A1 (en) * 2017-06-07 2018-12-13 Antibody Biopharm, Inc. Guided combinational therapeutic antibody
NZ761568A (en) 2017-08-02 2022-11-25 Phanes Therapeutics Inc Anti-cd47 antibodies and uses thereof
EP3695013A1 (en) * 2017-08-30 2020-08-19 Symphogen A/S Compositions and methods for treating cancer with anti-egfr antibodies
US11529425B2 (en) 2017-09-07 2022-12-20 Dingfu Biotarget Co., Ltd. Immunoconjugates comprising signal regulatory protein alpha
KR20190037164A (ko) * 2017-09-28 2019-04-05 한국과학기술연구원 신규 암 치료용 조성물
AU2018347521A1 (en) * 2017-10-12 2020-05-07 Immunowake Inc. VEGFR-antibody light chain fusion protein
CN111278865B (zh) * 2017-10-26 2023-04-25 盛禾(中国)生物制药有限公司 新的重组融合蛋白及其制备和用途
WO2019091473A1 (en) * 2017-11-10 2019-05-16 I-Mab Biopharma Co., Ltd. Fusion proteins containing cd47 antibodies and cytokines
WO2019095358A1 (zh) * 2017-11-20 2019-05-23 泰州迈博太科药业有限公司 一种靶向cd47与pd-l1的双功能融合蛋白
JP7231641B2 (ja) * 2017-12-04 2023-03-01 北京韓美薬品有限公司 天然抗体様構造を有し、ヘテロ二量体形態の抗ｐｄ－ｌ１／抗ｃｄ４７二重特異性抗体、ならびにその製造方法
WO2019109357A1 (zh) 2017-12-08 2019-06-13 杭州翰思生物医药有限公司 抗pd-1/cd47的双特异性抗体及其应用
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
AU2019235627B2 (en) * 2018-03-13 2026-01-15 Pfizer Inc. Improvements in CD47 blockade therapy by EGFR antibody
EP4144372A3 (en) 2018-03-21 2023-06-14 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
CN110386984B (zh) * 2018-04-17 2022-04-22 杭州尚健生物技术有限公司 结合cd47蛋白的融合蛋白及其应用
CN108794641A (zh) * 2018-07-04 2018-11-13 上海科医联创生物科技有限公司 一种针对EGFRvIII的多功能融合蛋白及其应用
US12134638B2 (en) * 2018-07-11 2024-11-05 Kahr Medical Ltd. SIRPalpha-4-1BBL variant fusion protein and methods of use thereof
MX2021000047A (es) 2018-07-11 2021-05-12 Kahr Medical Ltd Proteina de fusion variante pd1-4-1bbl y procedimientos de uso de la misma.
CN112533954B (zh) * 2018-08-08 2024-06-18 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和her2的重组双功能蛋白
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
EP3846855B1 (en) 2018-09-04 2024-12-04 Pfizer Inc. Cd47 blockade with parp inhibition for disease treatment
CN109535258A (zh) * 2018-10-26 2019-03-29 上海科弈药业科技有限公司 一种针对Her2+肿瘤的多功能融合蛋白及其应用
GB2596411B (en) * 2018-10-29 2023-09-20 Tigatx Inc Compositions and methods comprising IgA antibody constructs
CN111303293B (zh) 2018-11-14 2022-08-30 杭州尚健生物技术有限公司 一种融合蛋白及其用途
US12492231B2 (en) 2018-11-14 2025-12-09 Jn Biosciences Llc Multimeric hybrid Fc proteins for replacement of IVIG
US12180295B2 (en) * 2018-11-15 2024-12-31 Byondis B.V. Humanized anti-SIRPα antibodies
CN109517054B (zh) * 2018-12-04 2022-04-08 江苏东抗生物医药科技有限公司 SIRPα变体或其融合蛋白及其应用
CN109535263B (zh) * 2018-12-04 2022-06-17 江苏东抗生物医药科技有限公司 SIRPα突变体及其融合蛋白
JP7675012B2 (ja) 2018-12-21 2025-05-12 オーエスイー・イミュノセラピューティクス 二機能性抗ｐｄ－１／ｓｉｒｐａ分子
US20230012428A1 (en) * 2019-03-06 2023-01-12 Jiangsu Hengrui Medicine Co., Ltd. Bifunctional fusion protein and pharmaceutical use thereof
CN111763261B (zh) * 2019-04-02 2022-08-09 杭州尚健生物技术有限公司 一种融合蛋白及其用途
TW202045550A (zh) * 2019-04-05 2020-12-16 美商西建公司 腫瘤選擇性結合cd47之抗體之工程
AU2020282791A1 (en) 2019-05-31 2021-12-09 ALX Oncology Inc. Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor
CN114222586A (zh) * 2019-06-14 2022-03-22 斯克里普斯研究学院 免疫检查点阻断性双特异性分子
CN114072426B (zh) * 2019-07-08 2024-01-26 南京金斯瑞生物科技有限公司 抗cd47/抗pd-1双特异抗体及其制备方法和应用
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
WO2021013215A1 (zh) * 2019-07-23 2021-01-28 南京金斯瑞生物科技有限公司 抗cd47/抗lag-3双特异抗体及其制备方法和应用
EP4021485A1 (en) * 2019-08-28 2022-07-06 King's College London B cell targeted parallel car (pcar) therapeutic agents
CN118178645A (zh) 2019-10-18 2024-06-14 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
KR20220091576A (ko) 2019-10-31 2022-06-30 포티 세븐, 인코포레이티드 혈액암의 항-cd47 및 항-cd20 기반 치료
CA3157516A1 (en) * 2019-11-08 2021-05-14 Xinyan Zhao Anti-human programmed cell death ligand-1 (pd-l1) antibody and use thereof
BR112022008817A2 (pt) 2019-11-27 2022-07-26 Alx Oncology Inc Terapias combinadas para tratamento de câncer
HRP20241518T1 (hr) 2019-12-24 2025-01-03 Carna Biosciences, Inc. Spojevi koji moduliraju diacilglicerinkinazu
PH12022552122A1 (en) 2020-02-14 2024-01-29 Jounce Therapeutics Inc Antibodies and fusion proteins that bind to ccr8 and uses thereof
AU2021243864A1 (en) 2020-03-27 2022-11-03 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
CA3182607A1 (en) 2020-06-30 2022-01-06 Erik Hans MANTING Use of leukemia-derived cells in ovarian cancer vaccines
CN111808183B (zh) * 2020-07-25 2022-07-08 北京吉尔麦迪生物医药科技有限公司 一种靶向CD47的高亲和力SIRPα突变体及其融合蛋白
CN114195901A (zh) * 2020-09-17 2022-03-18 上海霖羲致企业管理有限公司 双特异性重组蛋白及其用途
CN116685348A (zh) * 2020-10-07 2023-09-01 细胞基因公司 淋巴恶性肿瘤病状的双特异性抗体治疗
JP2023552375A (ja) * 2020-12-06 2023-12-15 エーエルエックス オンコロジー インコーポレイテッド 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための多量体
CN112708675A (zh) * 2020-12-25 2021-04-27 中山大学肿瘤防治中心 骨髓nk细胞联合mcl1抑制剂在抗白血病中的应用
CN112656941A (zh) * 2021-01-20 2021-04-16 福建医科大学附属协和医院 抗cd47单克隆抗体在制备抗阿霉素耐药的急性淋巴细胞白血病细胞的药物中应用
WO2022190058A1 (en) 2021-03-12 2022-09-15 Dcprime B.V. Methods of vaccination and use of cd47 blockade
US20240182572A1 (en) * 2021-04-09 2024-06-06 Ose Immunotherapeutics Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
CA3216908A1 (en) 2021-05-13 2022-11-17 ALX Oncology Inc. Combination therapies for treating cancer
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
CN115636881B (zh) * 2021-07-19 2025-04-25 百奥泰生物制药股份有限公司 基于Luciferase报告基因系统的重组嵌合膜蛋白及其应用
KR20230016152A (ko) * 2021-07-19 2023-02-01 주식회사유한양행 Sirp-alpha 변이체 및 이의 용도
CN113956363B (zh) * 2021-10-13 2023-03-31 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和cd24的重组融合蛋白及其制备和用途
US20230183216A1 (en) 2021-10-28 2023-06-15 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
WO2023072217A1 (en) * 2021-10-28 2023-05-04 Guangzhou Lintonpharm Co., Ltd. Fusion proteins targeting cd3 and cd47
CR20240173A (es) 2021-10-29 2024-06-20 Gilead Sciences Inc Compuestos de cd73
US20250367255A1 (en) 2021-11-08 2025-12-04 Pfizer Inc. Enhancement Of CD47 Blockade Therapy With Anti-VEGF Agents
CN121108300A (zh) * 2021-12-21 2025-12-12 Fbd生物制品有限公司 工程改造的SIRPα变体及其使用方法
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
JP2024546851A (ja) 2021-12-22 2024-12-26 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
JP2025503731A (ja) * 2022-01-18 2025-02-04 エフビーデー バイオロジクス リミテッド Ｃｄ４７／ｐｄ－ｌ１を標的とするタンパク質複合体及びその使用方法
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
JP2025509610A (ja) 2022-03-17 2025-04-11 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
CA3246192A1 (en) 2022-03-24 2023-09-28 Bitterroot Bio, Inc. Modified FC-domain sirp-alpha fusion polypeptides
WO2023183890A1 (en) * 2022-03-24 2023-09-28 Bitterroot Bio, Inc. Multivalent sirp-alpha fusion polypeptides
AU2023239488A1 (en) * 2022-03-25 2024-11-14 WuXi Biologics Ireland Limited Anti-her2/anti-cd47 molecules and uses thereof
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
JP2025513258A (ja) 2022-04-21 2025-04-24 ギリアード サイエンシーズ， インコーポレイテッド Ｋｒａ ｇ１２ｄ調節化合物
CN120923632A (zh) * 2022-05-06 2025-11-11 正大天晴药业集团股份有限公司 靶向cd40和cd47的重组融合蛋白
US11807689B1 (en) * 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
IL317958A (en) 2022-07-01 2025-02-01 Gilead Sciences Inc CD73 compounds
AU2023307100A1 (en) 2022-07-12 2025-01-02 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
CN116041470B (zh) * 2022-08-04 2024-10-22 四川大学华西医院 具有高亲和力结合肿瘤细胞cd47的细胞膜材料及其制备方法和应用
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024061352A1 (zh) * 2022-09-23 2024-03-28 广州凌腾生物医药有限公司 分离的抗原结合蛋白及其应用
KR20250122479A (ko) 2022-12-22 2025-08-13 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
CN118546255A (zh) * 2023-02-24 2024-08-27 恒翼生物医药(上海)股份有限公司 一种靶向αvβ3和CD47的双功能融合蛋白以及其应用
WO2024193635A1 (en) * 2023-03-22 2024-09-26 Wangzhi LI Sirp variants and uses thereof
CN120882725A (zh) 2023-04-11 2025-10-31 吉利德科学公司 Kras调节化合物
CN121079300A (zh) 2023-04-21 2025-12-05 吉利德科学公司 Prmt5抑制剂及其用途
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930706D0 (en) 1999-12-24 2000-02-16 Medical Res Council Composition for inhibiting macrophage activity
US20090191202A1 (en) 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
US7820165B2 (en) 2005-11-21 2010-10-26 Merck Serono, S.A. Compositions and methods of producing hybrid antigen binding molecules and uses thereof
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
EP2573112A1 (en) 2007-10-11 2013-03-27 The Hospital For Sick Children Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
KR20110112299A (ko) 2008-12-19 2011-10-12 노파르티스 아게 자가면역 및 염증성 장애의 치료에 사용하기 위한 가용성 폴리펩티드
US10907209B2 (en) * 2009-05-15 2021-02-02 University Health Network Compositions and methods for treating hematological cancers targeting the SIRPα CD47 interaction
AU2010295661B2 (en) 2009-09-15 2015-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-CD47 therapy for hematologic cancers
LT3789038T (lt) 2010-05-14 2022-12-12 The Board Of Trustees Of The Leland Stanford Junior University Humanizuoti ir chimeriniai monokloniniai antikūnai prieš cd47
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
ES2808152T3 (es) 2011-11-28 2021-02-25 Merck Patent Gmbh Anticuerpos anti-PD-L1 y usos de los mismos
HUE050875T2 (hu) 2012-01-17 2021-01-28 Univ Leland Stanford Junior Nagy affinitású SIRP-alfa reagensek
EP4116331A1 (en) 2012-12-17 2023-01-11 PF Argentum IP Holdings LLC Treatment of cd47+ disease cells with sirp alpha-fc fusions
US9873747B2 (en) * 2013-01-31 2018-01-23 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
BR112015021921A2 (pt) 2013-03-15 2017-08-29 Merck Patent Gmbh Anticorpos biespecíficos tetravalente
KR102314088B1 (ko) 2014-03-24 2021-10-15 이뮨원코 바이오파마슈티컬즈 (상하이) 컴퍼니 리미티드 새로운 이중 기능성의 재조합 융합 단백질, 이의 제조 방법 및 용도
US10087257B2 (en) 2014-08-08 2018-10-02 The Board Of Trustees Of The Leland Stanford Junior University SIRP alpha-antibody fusion proteins
LT3180363T (lt) 2014-08-15 2019-11-25 Merck Patent Gmbh Sirp-alfa imunoglobulino sulieti baltymai

Also Published As

Publication number Publication date
HRP20191872T1 (hr) 2020-02-07
CN107108748A (zh) 2017-08-29
AU2015303135A1 (en) 2017-02-23
IL250622A0 (en) 2017-04-30
CA2956126A1 (en) 2016-02-18
BR112017002646A2 (pt) 2018-02-27
SI3180363T1 (sl) 2020-05-29
EP3180363B2 (en) 2022-09-14
IL250622B2 (en) 2023-04-01
IL250622B (en) 2022-12-01
EP3643727A1 (en) 2020-04-29
ES2751915T3 (es) 2020-04-02
RU2017108203A3 (lt) 2019-03-13
SG11201701189TA (en) 2017-03-30
JP6764858B2 (ja) 2020-10-07
MX2017001712A (es) 2017-04-27
ES2751915T5 (es) 2022-12-23
PL3180363T3 (pl) 2020-02-28
PT3180363T (pt) 2019-11-05
JP2017525698A (ja) 2017-09-07
ZA201701810B (en) 2020-10-28
US11021694B2 (en) 2021-06-01
DK3180363T3 (da) 2019-11-04
AU2015303135B2 (en) 2021-05-20
HUE046661T2 (hu) 2020-03-30
MX377196B (es) 2025-03-07
KR20170036796A (ko) 2017-04-03
EP3180363B1 (en) 2019-09-25
EP3180363A1 (en) 2017-06-21
WO2016024021A1 (en) 2016-02-18
US20160177276A1 (en) 2016-06-23
RU2017108203A (ru) 2018-09-17

Similar Documents

Publication Publication Date Title
ZA201701810B (en) Sirp-alpha immunoglobulin fusion proteins
IL254965B (en) fusion proteins
GB201509413D0 (en) Fusion protein
IL246355B (en) p97–ids fused proteins
EP3188758A4 (en) Sirp alpha-antibody fusion proteins
GB201504691D0 (en) Fusion protein
ZA202003845B (en) Fusion proteins
IL246348B (en) p97 fusion proteins
ZA201606327B (en) Uti fusion proteins
SG11201606501PA (en) Nanobody-fluorescent protein fusion
ZA201801394B (en) Fusion protein
GB201712792D0 (en) Fusion protein
GB201602850D0 (en) Fusion proteins
IL244857A0 (en) A fusion protein of acetylcholinesterase and the fc region
GB201617799D0 (en) Fusion polypeptide
GB201503789D0 (en) Fusion polypeptide
GB201409711D0 (en) MK-V fusion system